ADM Tronics Un (ADMT) AI Stock Analysis

• Market Cap: $5.75M
• Dividend Yield: N/A
• Average Volume (3M): 13.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.30
• Revenue Growth: 6.80%
• EPS Growth: 56.82%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 67,588,490
• 10 Day Avg. Volume: 10,740
• 30 Day Avg. Volume: 13,493
• PEG Ratio: 0.46
• Price to Book (P/B): 7.02
• Price to Sales (P/S): 1.47
• P/FCF Ratio: 472.30
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 1.86
• Enterprise Value/Gross Profit: 4.83
• Enterprise Value/Ebitda: 41.78
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $0.08 ▼(-28.18% Downside)
• Action: Reiterated Date: 03/18/26
• Date: Action: Reiterated 03/18/26

The score is primarily supported by improving financial performance, especially stronger cash generation and sharp revenue growth, but capped by still-fragile profitability and balance-sheet risk. Technically, the stock remains in a weak intermediate trend (below key moving averages) and looks stretched short-term, while valuation is constrained by a negative P/E and no dividend yield.

Positive Factors

Revenue Growth / Turnaround

A sustained TTM revenue surge (~159%) and recovery from prior heavy losses indicate improving commercial traction and scaling of operations. Over a 2–6 month horizon this growth supports operating leverage, higher absolute gross profit, and a stronger base to convert margins into durable profitability if maintained.

Cash Generation

Positive operating and free cash flow (~$438k TTM) demonstrates improved working-capital discipline and internal funding for operations and reinvestment. Durable cash generation reduces reliance on external financing, supports capex and debt service, and offers flexibility to sustain or expand core EMS activities.

Service-based EMS Model with Biotech Optionality

An EMS-focused business model yields recurring, contract-driven revenue and embedded customer relationships that can stabilize cash flow. The company's biotech/medical initiatives provide optional upside through licensing or product commercialization, offering diversification and potential higher-margin revenue streams if developed.

Negative Factors

Fragile Profitability

Margins remain fragile with a slightly negative net margin and negative EBIT, indicating profitability hasn’t been reliably achieved. This leaves the company exposed to cost inflation or revenue softness, limiting retained earnings and the ability to self-fund growth or build reserves over the medium term.

Leverage & Small Equity Base

Although leverage has improved, a ~0.83x debt-to-equity level and a small equity base raise solvency and refinancing risks for a microcap. If cash generation stalls, limited equity cushion constrains strategic flexibility and increases the probability of distress or dilutive financing over the next several quarters.

Limited Disclosure & Revenue Visibility

Lack of consistent public disclosure on product lines, end markets, and key customers reduces visibility into revenue durability and concentration risk. This opacity makes it harder to assess whether recent growth is repeatable or reliant on transitory contracts, raising execution uncertainty.

ADM Tronics Un Business Overview & Revenue Model

Company Description

ADM Tronics Unlimited, Inc., through its subsidiaries, develops, manufactures, and sells electronics for non-invasive medical and other applications in the United States, Australia, Asia, and Europe. It operates through Electronics, Chemical, and Engineering segments. The company offers proprietary devices for use in diagnostics and therapeutics of humans and animals; and electronic controllers for spas and hot tubs. It also provides water-based primers and adhesives; water-based coatings and resins; water-based chemical additives; and anti-static conductive paints, coatings, and other products. In addition, the company offers water-based, adhesive and related topical formulations for use in maxillofacial prosthetic medical applications; and for professional makeup applications primarily for film, TV, and theatrical productions. Further, it provides research, development, regulatory, and engineering services for the design, development, and manufacturing of medical devices, electronics, and other technologies and products, as well as medical electronic therapeutic technology. The company was incorporated in 1969 and is headquartered in Northvale, New Jersey.

How the Company Makes Money

ADMT’s primary way of generating revenue has historically been through electronics manufacturing services (EMS), where it earns income by providing services such as product design/engineering support, prototyping, and contract manufacturing/assembly for customer electronics (revenue recognized from customer orders and manufacturing contracts). In addition, the company has reported involvement in medical/biotech-related initiatives, which—when active—could generate revenue through product sales, licensing/royalties, milestone payments, or service/technology agreements; however, publicly available, current, and specific details on which of these streams are presently material (including named products, recurring contract customers, or significant partnerships) are not reliably available, so those specifics are null.

ADM Tronics Un Financial Statement Overview

Summary

Financials show a turnaround trajectory with strong TTM revenue growth and solid positive operating/free cash flow, but profitability is still not durable (slightly negative net margin and negative EBIT) and leverage remains a constraint despite improvement in debt-to-equity.

Income Statement

Results show a clear recovery from heavy losses in 2021–2024 toward near break-even profitability in TTM (Trailing-Twelve-Months): revenue grew strongly (TTM revenue growth ~159%) and gross margin held around the high-30% range. However, profitability is still fragile—TTM net margin is slightly negative and operating results remain pressured (EBIT is negative), indicating the turnaround is not fully proven and earnings quality remains volatile versus prior years’ deep losses.

Balance Sheet

Leverage is moderate but tightening: debt-to-equity improved versus the most recent annual level (about 1.26x in 2025 annual to ~0.83x in TTM), but equity is relatively small versus the asset base and returns to shareholders remain negative (TTM ROE slightly below zero). Overall, the balance sheet is serviceable, yet limited profitability and a still-elevated debt load for a small business increase downside risk if operations soften.

Cash Flow

Cash generation is the strongest area. TTM operating cash flow and free cash flow are solidly positive (~$438k) and improved meaningfully versus the prior annual period (which was near break-even), showing better working-capital/operating discipline. The key risk is consistency: earlier years had materially negative operating and free cash flow, so the current positive run needs to persist to support reinvestment and balance-sheet flexibility.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	3.41M	3.20M	2.85M	3.68M	3.21M	3.09M
Gross Profit	1.32M	1.40M	1.09M	1.66M	1.25M	1.16M
EBITDA	152.18K	12.29K	-514.02K	80.35K	-1.02M	-506.36K
Net Income	-6.75K	-123.06K	-716.85K	-96.32K	-1.38M	-598.28K
Balance Sheet
Total Assets	2.05M	2.13M	2.14M	3.09M	3.25M	5.21M
Cash, Cash Equivalents and Short-Term Investments	298.73K	382.97K	537.04K	1.00M	1.04M	1.55M
Total Debt	911.55K	846.86K	799.66K	752.69K	918.31K	1.58M
Total Liabilities	1.29M	1.46M	1.45M	1.52M	1.88M	2.46M
Stockholders Equity	761.21K	671.35K	692.39K	1.57M	1.37M	2.76M
Cash Flow
Free Cash Flow	438.10K	9.98K	-599.65K	125.02K	-574.95K	-769.64K
Operating Cash Flow	438.10K	9.98K	-585.13K	125.02K	-574.95K	-769.64K
Investing Cash Flow	-564.25K	-225.75K	-14.52K	0.00	0.00	0.00
Financing Cash Flow	-5.81K	61.70K	165.18K	-258.56K	66.50K	877.87K

ADM Tronics Un Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.11
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADMT, the sentiment is Negative. The current price of 0.11 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.09, and above the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.07 is Neutral, neither overbought nor oversold. The STOCH value of 78.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADMT.

ADM Tronics Un Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADMT	47 Neutral	$5.75M	-14.71	-13.70%	―	6.80%	56.82%
MOVE	47 Neutral	―	-27.76	-647.90%	―	-44.57%	55.97%
AEMD	45 Neutral	$2.95M	-0.28	-191.39%	―	―	76.53%
TIVC	45 Neutral	$2.33M	-0.37	-202.20%	―	-49.63%	82.22%
AMIX	40 Underperform	$5.24M	-0.38	-228.82%	―	―	63.87%